This site requires JavaScript and cookies to be enabled.

Icon: Graph showing improvement

Proven efficacy

Significant reduction in ADHD-RS-5 total score from CFB to EOS1

Adolescents 12 to 17 years of age

Adolescents 12 to 17 years of age

Inattention and hyperactivity/impulsivity symptom score reductions observed as early as week 2.1,2

Qelbree was studied in 4 clinical trials. In the study of adolescents 12 to 17 years of age, ADHD symptom score reductions were statistically significant for 400 mg, beginning at week 2.1-3

 

Efficacy Adolescents Large Image

The first nonstimulant approved for pediatric ADHD in over a decade1,4,5

Efficacy Adolescents Small Image

ADHD diagnosis based on ADHD-RS-5 screener and DSM-5 criteria

Phase III trials methodology1

The clinical trial was a randomized, double-blind, placebo-controlled, 3-arm, parallel-group, multicenter studies.

Primary endpoint1

CFB in the ADHD-RS-5 total score at EOS, Qelbree treatment group.

Inclusion criteria to include: males and females; adolescents 12 to 17 years; ADHD diagnosis based on criteria in the DSM-5, confirmed with the MINI-KID; ADHD-RS-5 total score of ≥28; CGI-S ≥4.1,2,6

Exclusion criteria to include: major psychiatric disorder (MDD history allowed); major neurobiological disorder; history of seizures; significant systemic disease; evidence of suicidality within prior 6 months before screening.2,6

Primary analysis is based on ITT population.1,2

Study P302 EOS=Week 6.1

Abbreviations: ADHD-RS-5, Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th ed; CFB, change from baseline; CGI-S, Clinical Global Impression–Severity of Illness; DSM-5, Diagnostic and Statistical Manual of Mental Disorders. 5th ed; EOS, end of study; ITT, intention to treat; MDD, major depressive disorder; MINI-KID, Mini-International Neuropsychiatric Interview for Children and Adolescents.

Simple to start1

 

Study P302: Titration at 1 week1,6

Age group: 12 to 17 years of age
ITT population: N=301
Study medication: 200 mg or matching placebo

Proven efficacy in robust clinical trials1

 

Primary efficacy measure: CFB to EOS on the ADHD-RS-5 Total Score vs placebo (N=301)1,2

Study P302 results:

ADHD-RS-5 total score at EOS was significantly reduced with Qelbree vs placebo. The CFB in the ADHD-RS-5 total score (LS mean ± SE) was -16.0 ± 1.45 for Qelbree 200 mg/day, -16.5 ± 1.38 for Qelbree 400 mg/day, and -11.4 ± 1.37 for placebo.1

  • Once-daily Qelbree delivers significant symptom score reductions on the subscales of both inattention and hyperactivity/impulsivity in children and adolescents1
  • Once-daily Qelbree demonstrates proven safety and tolerability and low discontinuation rates due to AEs in children and adolescents1,2

Abbreviations: ADHD-RS-5, Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th ed; AEs, adverse events; CFB, change from baseline; EOS, end of study.

Efficacy Adolescents Interior Small
Efficacy Adolescents Interior Large

Efficacy established in adolescents (12 to 17 years) in 1 randomized, placebo-controlled trial1

You might also be interested in:

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adult and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more]Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

 

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania, or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.

References:

1. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc.
2. Nasser A, Lirasno T, Adewole T, et al. A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2021; 41(8):370-372, 374-376.
3. Data on file, Supernus Pharmaceuticals.
4. INTUNIV [package insert]. Wayne, PA: Shire US, Inc.
5. US Food and Drug Administration. Summary review, NDA approval 22-037. September 2, 2009. Accessed October 21, 2021.
6. Nasser A, Kosheleff A, Hull J, et al. Translating attention-deficit/hyperactivity disorder rating scale-5 and Weiss functional impairment rating scale-parent effectiveness scores into clinical global impressions clinical significance levels in four randomized clinical trials of SPN-812 (viloxazine extended-release) in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2021; 31(2):215-216, 223.

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adult and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more]Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

 

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania, or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.